Lv4
728 积分 2024-06-11 加入
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
14小时前
求助中
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
14小时前
待确认
Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer
2天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2天前
已完结
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
11天前
已完结
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
15天前
已完结
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
22天前
已完结
MA11.06 A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies
23天前
已完结
Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort
23天前
已完结
Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC
23天前
已关闭
皖公网安备34019202002308
